Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 103,672	$ 304,962
Accounts receivable	21,710	12,388
Prepaid clinical development costs	986	844
Inventories, net	33,972	16,136
Other prepaid and current assets	10,328	11,566
Total current assets	170,668	345,896
Restricted cash	50,000	0
Property and equipment, net	817	1,276
Right of use operating lease assets	3,715	6,030
Intangible assets	56	56
Total assets	225,256	353,258
Current liabilities:
Accounts payable	20,745	51,975
Accrued clinical development costs	3,746	7,663
Other accrued liabilities	34,476	24,790
Revenue interest liability	14,048	5,392
Deferred revenue from collaborations	3,068	1,662
Operating lease liabilities	2,402	2,587
Total current liabilities	78,485	94,069
Convertible notes, net of issuance costs	272,508	179,367
Revenue interest liability	233,520	171,212
Operating lease liabilities	1,313	3,454
Deferred revenue from collaborations	845	0
Other long-term liabilities	1,290	1,290
Total liabilities	587,961	449,392
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of September 30, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized as of September 30, 2021 and December 31, 2020; 28,794,567 shares issued at September 30, 2021 and 27,910,366 shares issued at December 31, 2020	27	26
Additional paid-in capital	733,524	797,655
Treasury stock, at cost; 1,994,198 shares at September 30, 2021 and December 31, 2020	(54,998)	(54,998)
Accumulated deficit	(1,041,258)	(838,817)
Total stockholders’ deficit	(362,705)	(96,134)
Total liabilities and stockholders’ deficit	$ 225,256	$ 353,258